Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 EHA Meeting
Former TAP Partner
DUBLIN, May 12, 2022 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company present abstracts on Vyxeos®/Vyxeos® Liposomal (daunorubicin and cytarabine), also known as JZP351 at the 27th Annual Congress of the European Hematology Association (EHA) from June 9 –12, 2022.
The Jazz-supported presentations at the EHA 27th Congress are:
Vyxeos Liposomal Presentations
|
Presentation Title |
Author |
Presentation Details |
|
Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed acute myeloid leukemia who are unfit for intensive chemotherapy |
Uy L. G. et al. |
Type: Poster Date: June 10 at 16:30 CEST Abstract number: P515 |
|
CPX-351 treatment for acute myeloid leukemia in England: Real-world outcomes in adults aged <60 years versus >60 years |
Legg A. et al. |
Type: Poster Date: June 10 at 16:30 CEST Abstract number: P513 |
|
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia |
McCloskey J, et al
|
Type: Poster Date: June 10 at 16:30 CEST Abstract number: P514 |
|
Real life experience using front-line CPX-351 for therapy-related and AML-MRC: results from the Spanish PETHEMA registry (IST) |
Bernal T, et al |
Type: Poster Date: June 10 at 16:30 CEST Abstract number: P508 |
|
A randomised comparison of CPX-351 and FLAG-Ida in high risk acute myeloid leukaemia. Results from the NCRI AML19 trial |
Russel N, et al |
Type: Oral presentation Date: June 11 Abstract number: S128 |